FDA Approves First At-Home Starting Dose for Leqembi Alzheimer’s Treatment
RBC keeps Outperform at $242, Truist upgrades to Buy ($235 target).
/ 352 items
#XY Event-Driven Stocks↓
Oncolytics Biotech Advances REO 033 Trial with Promising Pelareorep Data in Hard-to-Treat Colorectal Cancer
New sites opening, patients enrolling, and FDA Type D meeting planned for August 2026.
Enlivex Secures FDA RMAT Designation for Allocetra in Knee Osteoarthritis
Phase IIb trial now underway with first U.S. patient dosed.
TNXP Stock Rises on Expanded Medicare Access for Fibromyalgia Drug TONMYA
Tonix secured expanded Medicare coverage for its fibromyalgia drug TONMYA, reaching approximately 9 million additional patients starting January 2027.
Bempikibart Delivers Promising Hair Regrowth in Alopecia Trial, Sending Q32 Bio Stock Soaring
The experimental treatment showed meaningful hair regrowth and a favorable safety profile.
Bausch + Lomb Discontinues BL1107 Eye Drops for Glaucoma After Phase 2 Miss
The company will discontinue the topical program but continue advancing a sustained-release implant for geographic atrophy.